Sasa M, Kondo K, Komaki K, Morimoto T, Monden Y
Second Department of Surgery, School of Medicine, University of Tokushima, Japan.
J Surg Oncol. 1994 May;56(1):46-50. doi: 10.1002/jso.2930560110.
Seventy tumors of invasive ductal carcinoma of the breast were examined for p53 alteration by the RT-PCR-SSCP method. Sixty-five samples (92.9%) were investigated in the regions of codons 101-200 and 201-300. In total, 16 samples (24.6%) showed p53 gene alteration. We found that p53 gene alteration showed a correlation with (1) a negative ER status, (2) a negative PgR status, and (3) a high histologic grade (especially numerous mitotic figures) of the tumor. However, we found no correlation between p53 gene alteration and the lymph node status or clinical stage. Thus, p53 gene alteration in breast cancer may occur in highly malignant breast cancer other than advanced clinical stage cancer or node-positive cancer.
采用逆转录-聚合酶链反应-单链构象多态性（RT-PCR-SSCP）方法检测了70例乳腺浸润性导管癌肿瘤的p53改变情况。对65个样本（92.9%）进行了密码子101-200和201-300区域的研究。总共16个样本（24.6%）显示出p53基因改变。我们发现p53基因改变与以下因素相关：（1）雌激素受体（ER）阴性状态；（2）孕激素受体（PgR）阴性状态；（3）肿瘤的高组织学分级（尤其是大量核分裂象）。然而，我们未发现p53基因改变与淋巴结状态或临床分期之间存在相关性。因此，乳腺癌中的p53基因改变可能发生在高恶性乳腺癌中，而非晚期临床分期癌症或淋巴结阳性癌症。
